Catalyst

Slingshot members are tracking this event:

Acadia (ACAD) Expects Top-Line Phase 2 Data Evaluating NUPLAZID in Alzheimer's Disease Psychosis in Q4 2016

Source Link:
http://seekingalpha.com/article/3940786-acadia-pharmaceuticals-acad-ceo-steve-davis-q4-2015-results-earnings-call-transcript?part=single

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
ACAD
100%
SIGN ME UP
I want to vote! LOG ME IN
Now!
Slingshot Insights Explained
JOIN FOR FREE TODAY
Catalyst Date
Occurred on:
Dec 20, 2016
Occurred Source:
http://news.acadia-pharm.com/phoenix.zhtml?c=125180&p=irol-newsArticle&ID=2230818
Related Projects Image
Related Keywords Top-line Data, Study 019, Nuplazid, Pimavanserin, Phase 2
About Us
Media Center
Connect with Us
© 2024 Slingshot Insights. All rights reserved.